Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
TLX-250 by Telix Pharmaceuticals for Metastatic Renal Cell Carcinoma: Likelihood of Approval
TLX-250 is under clinical development by Telix Pharmaceuticals and currently in Phase II for Metastatic Renal Cell Carcinoma. According to...
Data Insights
TLX-250 by Telix Pharmaceuticals for Solid Tumor: Likelihood of Approval
TLX-250 is under clinical development by Telix Pharmaceuticals and currently in Phase I for Solid Tumor. According to GlobalData, Phase...